
pmid: 21843682
This commentary explains why the Food and Drug Administration (FDA) should remove the black box warning regarding skeletal health on the package labeling for the injectable contraceptive depot medroxyprogesterone acetate (DMPA). It states that by depriving women of long-term use of this safe effective product this black box warning hurts the public health. Copyright © 2011 Elsevier Inc. All rights reserved.
Intrauterine Devices, Medicated, Medroxyprogesterone Acetate, Drug Utilization, Postmenopause, Fractures, Bone, Prescriptions, Bone Density, Pregnancy, Contraceptive Agents, Female, Humans, Female, Practice Patterns, Physicians', Drug Labeling
Intrauterine Devices, Medicated, Medroxyprogesterone Acetate, Drug Utilization, Postmenopause, Fractures, Bone, Prescriptions, Bone Density, Pregnancy, Contraceptive Agents, Female, Humans, Female, Practice Patterns, Physicians', Drug Labeling
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 21 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
